Skip to main content

CORRECTION article

Front. Immunol., 19 December 2024
Sec. Multiple Sclerosis and Neuroimmunology
Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1535051

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis

This article is a correction to:

  1. Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis

    1. Read original article
Fernando Rodríguez-Jorge&#x;Fernando Rodríguez-Jorge1†Jos Ignacio Fernndez-Velasco*&#x;&#x;José Ignacio Fernández-Velasco2*†‡Noelia VillarrubiaNoelia Villarrubia2Julia Gracia-GilJulia Gracia-Gil3Eva FernndezEva Fernández3Virginia Meca-LallanaVirginia Meca-Lallana4Carolina Díaz-PrezCarolina Díaz-Pérez4Susana Sainz de la MazaSusana Sainz de la Maza2Eva María PachecoEva María Pacheco5Ana QuirogaAna Quiroga6Lluis Rami-TorrentLluis Ramió-Torrentà6Sergio Martínez-YlamosSergio Martínez-Yélamos7Laura BauLaura Bau7Enric MonrealEnric Monreal1Ana Lpez-RealAna López-Real8Alexander Rodero-RomeroAlexander Rodero-Romero2Laura BorregaLaura Borrega9Santiago DíazSantiago Díaz10Pablo EguíaPablo Eguía10Mercedes EspioMercedes Espiño2Juan Luis Chico-GarcíaJuan Luis Chico-García1Francisco Javier BarreroFrancisco Javier Barrero11María Luisa Martínez-GinsMaría Luisa Martínez-Ginés12Jos Manuel García-DomínguezJosé Manuel García-Domínguez12Soraya De la FuenteSoraya De la Fuente13Irene MorenoIrene Moreno14Raquel Sainz-Amo,Raquel Sainz-Amo1,2M. Alba Ma-MartínezM. Alba Mañé-Martínez15Ana CamineroAna Caminero16Fernando Castellanos-PinedoFernando Castellanos-Pinedo17Ana Gmez LpezAna Gómez López13Andrs Labiano-FontcubertaAndrés Labiano-Fontcuberta13Lucía AyusoLucía Ayuso18Rossana AbreuRossana Abreu19Miguel ngel HernndezMiguel Ángel Hernández19Jos Meca-LallanaJosé Meca-Lallana20Lorena Martín-AguilarLorena Martín-Aguilar21Alfonso Muriel GarcíaAlfonso Muriel García22Jaime MasjuanJaime Masjuan1Lucienne Costa-FrossardLucienne Costa-Frossard1Luisa María VillarLuisa María Villar2
  • 1Neurology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
  • 2Immunology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
  • 3Neurology Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain
  • 4Neurology Department, Hospital Universitario La Princesa, Madrid, Spain
  • 5Neurology Department, Hospital Universitario Juan Ramon Jimenez, Huelva, Spain
  • 6Neurology Department, Hospital Universitario de Gerona Doctor Josep Trueta, Gerona, Spain
  • 7Neurology Department, Hospital Universitario de Bellvitge, Barcelona, Spain
  • 8Neurology Department, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain
  • 9Neurology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
  • 10Neurology Department, Hospital Universitario Gran Canaria Doctor Negrín, Gran Canaria, Spain
  • 11Neurology Department, Hospital Universitario Clínico San Cecilio Granada, Granada, Spain
  • 12Neurology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
  • 13Neurology Department, Hospital Universitario Doce de Octubre, Madrid, Spain
  • 14Neurology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
  • 15Neurology Department, Hospital Universitario Joan XXII, Tarragona, Spain
  • 16Neurology Department, Complejo Asistencial de Ávila, Ávila, Spain
  • 17Neurology Department, Hospital Virgen del Puerto, Cáceres, Spain
  • 18Neurology Department, Hospital Universitario Principe de Asturias, Madrid, Spain
  • 19Neurology Department, Hospital Universitario Nuestra Señora Candelaria, Tenerife, Spain
  • 20Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
  • 21Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  • 22Biostatistics Department, Hospital Universitario Ramón y Cajal, Madrid, Spain

A Corrigendum on
Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis.

By Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos-Pinedo F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L and Villar LM (2024) Front. Immunol. 15:1480676. doi: 10.3389/fimmu.2024.1480676

In the published article, an author name was incorrectly written as “Fernando Castellanos”. The correct spelling is “Fernando Castellanos-Pinedo”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: multiple sclerosis, ocrelizumab, neurofilament light chain, glial fibrillary acidic protein, serum biomarkers

Citation: Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos-Pinedo F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L and Villar LM (2024) Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis. Front. Immunol. 15:1535051. doi: 10.3389/fimmu.2024.1535051

Received: 26 November 2024; Accepted: 28 November 2024;
Published: 19 December 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Rodríguez-Jorge, Fernández-Velasco, Villarrubia, Gracia-Gil, Fernández, Meca-Lallana, Díaz-Pérez, Sainz de la Maza, Pacheco, Quiroga, Ramió-Torrentà, Martínez-Yélamos, Bau, Monreal, López-Real, Rodero-Romero, Borrega, Díaz, Eguía, Espiño, Chico-García, Barrero, Martínez-Ginés, García-Domínguez, De la Fuente, Moreno, Sainz-Amo, Mañé-Martínez, Caminero, Castellanos-Pinedo, Gómez López, Labiano-Fontcuberta, Ayuso, Abreu, Hernández, Meca-Lallana, Martín-Aguilar, Muriel García, Masjuan, Costa-Frossard and Villar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: José Ignacio Fernández-Velasco, amZ2ZWxhc2NvQHNhbHVkLm1hZHJpZC5vcmc=

†These authors have contributed equally to this work and share first authorship

‡ORCID: José Ignacio Fernández-Velasco, orcid.org/0000-0001-9148-671X

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.